140 related articles for article (PubMed ID: 38869744)
1. Insight into Cardioprotective Effects and Mechanisms of Dexmedetomidine.
Jiang L; Xiong W; Yang Y; Qian J
Cardiovasc Drugs Ther; 2024 Jun; ():. PubMed ID: 38869744
[TBL] [Abstract][Full Text] [Related]
2. Dexmedetomidine Attenuates Ischemia/Reperfusion-Induced Myocardial Inflammation and Apoptosis Through Inhibiting Endoplasmic Reticulum Stress Signaling.
Yang YF; Wang H; Song N; Jiang YH; Zhang J; Meng XW; Feng XM; Liu H; Peng K; Ji FH
J Inflamm Res; 2021; 14():1217-1233. PubMed ID: 33833544
[TBL] [Abstract][Full Text] [Related]
3. Dexmedetomidine Preconditioning Attenuates Myocardial Ischemia/Reperfusion Injury in Rats by Suppressing Mitophagy Via Activating Α2-Adrenergic Receptor.
Chen Y; Chen H; Chen Y; Yang Z; Zhou T; Xu W
Arq Bras Cardiol; 2023 Oct; 120(10):e20220750. PubMed ID: 37909577
[TBL] [Abstract][Full Text] [Related]
4. Amelioration of myocardial ischemia/reperfusion injury in diabetes: A narrative review of the mechanisms and clinical applications of dexmedetomidine.
Sun M; Wang R; Xia R; Xia Z; Wu Z; Wang T
Front Pharmacol; 2022; 13():949754. PubMed ID: 36120296
[TBL] [Abstract][Full Text] [Related]
5. Dexmedetomidine Maintains Its Direct Cardioprotective Effect Against Ischemia/Reperfusion Injury in Hypertensive Hypertrophied Myocardium.
Yoshikawa Y; Hirata N; Kawaguchi R; Tokinaga Y; Yamakage M
Anesth Analg; 2018 Feb; 126(2):443-452. PubMed ID: 28914648
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of Dexmedetomidine Postconditioning in the Field of Myocardial Ischemia-Reperfusion Injury.
Bunte S; Behmenburg F; Majewski N; Stroethoff M; Raupach A; Mathes A; Heinen A; Hollmann MW; Huhn R
Anesth Analg; 2020 Jan; 130(1):90-98. PubMed ID: 31633505
[TBL] [Abstract][Full Text] [Related]
7. α2-adrenoreceptor modulated FAK pathway induced by dexmedetomidine attenuates pulmonary microvascular hyper-permeability following kidney injury.
Chen Q; Yi B; Ma J; Ning J; Wu L; Ma D; Lu K; Gu J
Oncotarget; 2016 Aug; 7(35):55990-56001. PubMed ID: 27463003
[TBL] [Abstract][Full Text] [Related]
8. Dexmedetomidine as a cardioprotective drug: a narrative review.
Takahashi K; Yoshikawa Y; Kanda M; Hirata N; Yamakage M
J Anesth; 2023 Dec; 37(6):961-970. PubMed ID: 37750978
[TBL] [Abstract][Full Text] [Related]
9. Dexmedetomidine attenuates lung apoptosis induced by renal ischemia-reperfusion injury through α
Li J; Chen Q; He X; Alam A; Ning J; Yi B; Lu K; Gu J
J Transl Med; 2018 Mar; 16(1):78. PubMed ID: 29566706
[TBL] [Abstract][Full Text] [Related]
10. Dexmedetomidine pretreatment protects the heart against apoptosis in ischemia/reperfusion injury in diabetic rats by activating PI3K/Akt signaling in vivo and in vitro.
Chang JH; Jin MM; Liu JT
Biomed Pharmacother; 2020 Jul; 127():110188. PubMed ID: 32407987
[TBL] [Abstract][Full Text] [Related]
11. Dexmedetomidine protects the heart against ischemia-reperfusion injury by an endothelial eNOS/NO dependent mechanism.
Riquelme JA; Westermeier F; Hall AR; Vicencio JM; Pedrozo Z; Ibacache M; Fuenzalida B; Sobrevia L; Davidson SM; Yellon DM; Sánchez G; Lavandero S
Pharmacol Res; 2016 Jan; 103():318-27. PubMed ID: 26607864
[TBL] [Abstract][Full Text] [Related]
12. The cardioprotective effect of dexmedetomidine on regional ischemia/reperfusion injury in type 2 diabetic rat hearts.
Deng L; Chen H; Wei N; Zhang Z; Wang G
Microvasc Res; 2019 May; 123():1-6. PubMed ID: 30179598
[TBL] [Abstract][Full Text] [Related]
13. Dexmedetomidine administration before, but not after, ischemia attenuates intestinal injury induced by intestinal ischemia-reperfusion in rats.
Zhang XY; Liu ZM; Wen SH; Li YS; Li Y; Yao X; Huang WQ; Liu KX
Anesthesiology; 2012 May; 116(5):1035-46. PubMed ID: 22417965
[TBL] [Abstract][Full Text] [Related]
14. Dexmedetomidine attenuates renal fibrosis via α2-adrenergic receptor-dependent inhibition of cellular senescence after renal ischemia/reperfusion.
Li Q; Chen C; Chen X; Han M; Li J
Life Sci; 2018 Aug; 207():1-8. PubMed ID: 29729264
[TBL] [Abstract][Full Text] [Related]
15. Dexmedetomidine Improves Cardiovascular and Ventilatory Outcomes in Critically Ill Patients: Basic and Clinical Approaches.
Castillo RL; Ibacache M; Cortínez I; Carrasco-Pozo C; Farías JG; Carrasco RA; Vargas-Errázuriz P; Ramos D; Benavente R; Torres DH; Méndez A
Front Pharmacol; 2019; 10():1641. PubMed ID: 32184718
[TBL] [Abstract][Full Text] [Related]
16. Dexmedetomidine attenuates myocardial ischemia-reperfusion injury in vitro by inhibiting NLRP3 Inflammasome activation.
Huang Y; Sun X; Juan Z; Zhang R; Wang R; Meng S; Zhou J; Li Y; Xu K; Xie K
BMC Anesthesiol; 2021 Apr; 21(1):104. PubMed ID: 33823789
[TBL] [Abstract][Full Text] [Related]
17. Dexmedetomidine protects the heart against ischemia reperfusion injury via regulation of the bradykinin receptors.
Song J; Du J; Tan X; Wu Z; Yuan J; Cong B
Eur J Pharmacol; 2021 Nov; 911():174493. PubMed ID: 34506777
[TBL] [Abstract][Full Text] [Related]
18. Dexmedetomidine preconditioning for myocardial protection in ischaemia-reperfusion injury in rats by downregulation of the high mobility group box 1-toll-like receptor 4-nuclear factor κB signalling pathway.
Yang YF; Peng K; Liu H; Meng XW; Zhang JJ; Ji FH
Clin Exp Pharmacol Physiol; 2017 Mar; 44(3):353-361. PubMed ID: 27998004
[TBL] [Abstract][Full Text] [Related]
19. Dexmedetomidine: a review of applications for cardiac surgery during perioperative period.
Zhang X; Zhao X; Wang Y
J Anesth; 2015 Feb; 29(1):102-11. PubMed ID: 24913070
[TBL] [Abstract][Full Text] [Related]
20. Dexmedetomidine protects cardiac microvascular endothelial cells from the damage of ogd/r through regulation of the pparδ-mediated autophagy.
Shao Q; Xia J; Wu P; Ying J
Microcirculation; 2021 May; 28(4):e12675. PubMed ID: 33377581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
